Rieke E Alten

45PUBLICATIONS
95CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Time-series analysisHaematological tumoursPharmacogenomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (45)

|Jan 12, 2026
Rationale, Design and Methods of the Filgotinib Initial Response Study in Rheumatoid Arthritis (FIRST-RA).

Georg Pongratz, Rieke Alten, Torsten Witte

|Dec 23, 2025
Long-Term Effectiveness of Baricitinib and Other b/tsDMARDs in Patients with Rheumatoid Arthritis with Early Low Disease Activity or Remission: 2-Year Data from the RA-BE-REAL Study.

Rieke Alten, Andrew Östör, Christopher J Edwards

|Nov 20, 2025
Correction to: Comparative Effectiveness, Time to Discontinuation, and Patient-Reported Outcomes with Baricitinib in Rheumatoid Arthritis: 2-Year Data from the Multinational, Prospective Observational RA-BE-REAL Study in European Patients.

Rieke Alten, Gerd R Burmester, Marco Matucci-Cerinic

|Jan 30, 2025
Safety and efficacy of filgotinib in patients with rheumatoid arthritis: final results of the DARWIN 3 long-term extension study.

Rene Westhovens, Kevin L Winthrop, Arthur Kavanaugh

|Sep 21, 2024
Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study.

Lars Erik Kristensen, Khai Jing Ng, Marcus Ngantcha

|Mar 13, 2024
Impact of filgotinib on pain control in the phase 3 FINCH studies.

Peter C Taylor, Arthur Kavanaugh, Peter Nash

Pageof 8

Frequent Collaborators

5 joint publications

Rene Westhovens

4 joint publications

Mark C Genovese

3 joint publications

Peter C Taylor

3 joint publications

Steven Simoens